Please login to the form below
Data by
2
Revenue 2014Pfizer
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Pfizer's 2013 sales performance.
FDA clears Pfizer's leukaemia drug Besponsa
FDA clears Pfizer's leukaemia drug Besponsa. The breakthrough treatment is the first CD22-targeted ADC to be approved in the US. ... It is the first CD22-targeted ADC to be approved for marketing in the US, according to Pfizer.
Ron Menezes joins Almirall’s Aqua Pharmaceuticals
Pfizer. Eduardo Sanchiz, chief executive officer at Almirall, said: “We are very pleased to announce the appointment of Ron Menezes as the new president and GM of Aqua Pharmaceuticals.
Biocon backs away from biosimilar filings in Europe
and Celltrion and Pfizer's Hospira unit which have a candidate in late-stage development time to catch up.
NICE set to reject Pfizer's leukaemia drug Besponsa
NICE set to reject Pfizer's leukaemia drug Besponsa. Firm plans to appeal the final appraisal determination on its orphan drug. ... The National Institute of Healthcare and Excellence (NICE) is set to reject Pfizer’s orphan drug for leukaemia Besponsa
BMS data add to checkpoint inhibitor combo confusion
The CheckMate-214 trial compared Opdivo and Yervoy to Pfizer's targeted RCC therapy Sutent (sunitinib) in patients with previously-untreated RCC.
| Global revenue 2014 |
|---|
| 1: Novartis |
| 2: Pfizer |
| 3: Roche |
| 4: Sanofi |
| 5: Merck & Co. |
| 6: Johnson & Johnson |
| 7: GlaxoSmithKline |
| 8: AstraZeneca |
| 9: Gilead Sciences |
| 10: Takeda |
| 11: AbbVie |
| 12: Amgen |
| 13: Teva |
| 14: Lilly |
| 15: Bristol-Myers Squibb |
| 16: Bayer |
| 17: Novo Nordisk |
| 18: Astellas |
| 19: Boehringer Ingelheim |
| 20: Actavis |
| 21: Otsuka |
| 22: Daiichi Sankyo |
| 23: Biogen Idec |
| 24: Baxter |
| 25: Merck KGaA |
| US revenue 2014 |
|---|
| 1: Gilead Sciences |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Roche |
| 5: Novartis |
| 6: Amgen |
| 7: Merck & Co. |
| 8: Sanofi |
| 9: AbbVie |
| 10: Actavis |
| 11: AstraZeneca |
| 12: GlaxoSmithKline |
| 13: Lilly |
| 14: Bristol-Myers Squibb |
| 15: Novo Nordisk |
| Oncology revenue 2014 |
|---|
| 1: Roche |
| 2: Novartis |
| 3: Celgene |
| 4: Johnson & Johnson |
| 5: Bristol-Myers Squibb |
| 6: Lilly |
| 7: Takeda |
| 8: AstraZeneca |
| 9: Merck & Co. |
| 10: Amgen |
| 11: Pfizer |
| 12: Astellas |
| 13: Bayer |
| 14: Otsuka |
| 15: Sanofi |
| 16: Merck KGaA |
| 17: Eisai |
| 18: AbbVie |
| 19: Pharmacyclics |
| 20: Incyte |
| Immunology revenue 2014 |
|---|
| 1: AbbVie |
| 2: Johnson & Johnson |
| 3: Pfizer |
| 4: Amgen |
| 5: Merck & Co. |
| 6: Astellas |
| 7: Roche |
| 8: Novartis |
| 9: Bristol-Myers Squibb |
| 10: Mitsubishi Tanabe |
| 11: UCB |
| 12: Hisamitsu |
| 13: Daiichi Sankyo |
| 14: Takeda |
| CNS revenue 2014 |
|---|
| 1: Pfizer |
| 2: Biogen Idec |
| 3: Novartis |
| 4: Otsuka |
| 5: Teva |
| 6: Johnson & Johnson |
| 7: Lilly |
| 8: Merck KGaA |
| 9: AstraZeneca |
| 10: Shire |
| 11: Bristol-Myers Squibb |
| 12: UCB |
| 13: Lundbeck |
| 14: Eisai |
| 15: GlaxoSmithKline |
| 16: Sanofi |
| 17: Mylan |
| 18: Indivior |
| 19: Actavis |
| 20: Bayer |
| Cardiovascular revenue 2014 |
|---|
| 1: AstraZeneca |
| 2: Sanofi |
| 3: Merck & Co. |
| 4: Daiichi Sankyo |
| 5: Pfizer |
| 6: Novartis |
| 7: Bayer |
| 8: Takeda |
| 9: Boehringer Ingelheim |
| 10: Astellas |
| 11: Actelion |
| 12: Johnson & Johnson |
| 13: Shionogi |
| 14: United Therapeutics |
| 15: Bristol-Myers Squibb |
| 16: Gilead Sciences |
| 17: Otsuka |
| 18: Roche |
| 19: Lilly |
| 20: The Medicines Company |
| Biologic revenue 2014 |
|---|
| 1: Roche |
| 2: Amgen |
| 3: Novo Nordisk |
| 4: AbbVie |
| 5: Sanofi |
| 6: Johnson & Johnson |
| 7: Pfizer |
| 8: Merck & Co. |
| 9: Lilly |
| 10: Biogen Idec |
| 11: Merck KGaA |
| 12: GlaxoSmithKline |
| 13: Bristol-Myers Squibb |
| 14: Novartis |
| 15: Bayer |
Data by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
Featured jobs
- Account Manager, Medical Communications
-
£30, 000-£40, 000
-
Principal Medical Writer
-
Great salary and benefits
- JAM – Med Comms – Independent Agency
-
Salary TBC
- Senior Account Manager/ Account Director – Pharma and Life Scien...
-
Competitive Salary
- Director of Scientific and Editorial Services
-
Great salary and benefits - Circa 100K
- Account Executive - Pharma and Life Sciences Brighton or Maccles...
-
Competitive Salary
- Head of Communications - Based Cambridge
-
Excellent Basic and Flex Benefits
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Account Manager – Healthcare Advertising
-
Salary TBC
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Editorial Director - BioScience
-
Competitive Salary
- Freelance Medical Copywriter, Healthcare Advertising Agency
-
according to skills and experience
- Principal Medical Writer, Medical Education Agency
-
£46, 000 – £56, 000 benefits
-
Brand Manager
-
Competitive salary and package
Subscribe to our email news alerts
- Novartis trial marks ResearchKit first in MS
- Samsung deal with Takeda looks beyond biosimilars
- Ocrevus off to a flying start as Roche raises 2017 forecasts
- NICE set to reject Pfizer's leukaemia drug Besponsa
- Biocon backs away from biosimilar filings in Europe
- Astellas extends phase III programme for Rydapt rival gilteritinib
- Hugh Cole joins Jounce Therapeutics as chief business officer
- PharmaLex appoints Dr Adam King to its regulatory team
- The Pharma Wars Series
- Ironwood claims FDA OK for former AZ gout drug
- Astellas extends phase III programme for Rydapt rival gilteritinib
- What pharma marketers can learn from growth hacking?
PMHub
Streaming Well
Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....
Latest intelligence
- The Pharma Wars Series
- The future galaxy is complex. Where markets are more competitive and customers more segmented, you’ve got to be smarter. But not only smarter, the Jedi today needs to be everywhere...
- What pharma marketers can learn from growth hacking?
- Growth hackers instinctively blend technical skills with creative thinking...
- The sound of silence puts the squeeze on generics and biosimilars
- Medicines for Europe vows to get governments talking to realise potential...
Quick links
Infographics
